Reuters logo
BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis
September 14, 2017 / 1:09 PM / 12 days ago

BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

Sept 14 (Reuters) - Incyte Corp:

* Baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

* Incyte Corp - ‍results showed baricitinib in combination with mid-potency tcs significantly improved signs, symptoms of ad compared to tcs alone​

* Incyte Corp - ‍Lilly will initiate a phase 3 clinical program for moderate-to-severe atopic dermatitis later this year​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below